Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1056/nejmoa0801479 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma |
| https://doi.org/10.1038/leu.2017.138 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study |
| https://doi.org/10.1111/j.1600-0609.2010.01533.x | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study |
| https://doi.org/10.1111/j.1600-0609.2011.01599.x | Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma |
| https://doi.org/10.1210/jcem.81.5.8626853 | High-dose growth hormone treatment of short children born small for gestational age. |
| https://doi.org/10.1210/jcem-63-2-376 | Pubertal Growth and Final Height in Hypopituitary Boys: A Minor Role of Bone Age at Onset of Puberty* |
| https://doi.org/10.1182/blood.v118.21.476.476 | Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial |
| Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency. | |
| https://doi.org/10.1182/blood.v128.22.4414.4414 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study |
| https://doi.org/10.1182/blood.v112.11.650.650 | Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma |
| https://doi.org/10.1182/blood.v116.21.13.13 | Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group |
| https://doi.org/10.1182/blood.v112.11.54.54 | Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial |
| https://doi.org/10.1182/blood.v124.21.80.80 | Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma |
| https://doi.org/10.1182/blood.v112.11.2778.2778 | Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone |
| https://doi.org/10.1182/blood.v116.21.1083.1083 | Do Early Events Excluding Patients with Acute Promyelocytic Leukemia (APL) From Trial Enrollment Modify Treatment Result Evaluation? Real-Life Management of 100 Patients Referred to the University Hospital Saint-Louis Between 2000 and 2010. |
| https://doi.org/10.1159/000117389 | Concerns, Expectations and Perception Regarding Stature, Physical Appearance and Psychosocial Functioning before and during High-Dose Growth Hormone Treatment of Short Pre-pubertal Children Born Small for Gestational Age |
| https://doi.org/10.1159/000339829 | Insulin Sensitivity Modulates the Growth Response during the First Year of High-Dose Growth Hormone Treatment in Short Prepubertal Children Born Small for Gestational Age |
| https://doi.org/10.1182/blood.v110.11.76.76 | MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma. |
| https://doi.org/10.1182/blood.v114.22.3859.3859 | Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use. |
| https://doi.org/10.1182/blood.v112.11.1727.1727 | Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study. |
| https://doi.org/10.1182/blood.v114.22.845.845 | Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups. |
| https://doi.org/10.1182/blood.v116.21.1084.1084 | Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials. |
| https://doi.org/10.1182/blood.v124.21.4770.4770 | Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma |
| https://doi.org/10.1182/blood.v112.11.1741.1741 | Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial. |
| https://doi.org/10.1182/blood.v106.11.890.890 | Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials). |
| https://doi.org/10.1182/blood.v106.11.544.544 | Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results. |
| https://doi.org/10.1182/blood.v116.21.1078.1078 | High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL). |